MENU
 

PRE TAX NTA |$3.53

Value as at close of business on 7 March 2025

Moderna’s miracle and why mRNA is the new powerhouse of medicine

The powerful technology that has enabled mRNA vaccines to save millions of lives during the coronavirus pandemic has much broader potential, according Bob Langer, one of the co-founders of Moderna.

As a key attraction at the Sohn Hearts & Minds 2021 Investment Leaders Conference in Australia in early December, he will be expounding on this breakthrough technology and what it means for the biotech industry.‍

Professor Langer, the most cited engineer in the world, is expecting to see an expansion of mRNA, not only with improvements in vaccines for COVID-19, but also vaccines for other diseases such as flu, viral respiratory conditions and cancer. He is also expecting new RNA drugs for rare diseases.

“At Moderna alone, we have 13 or 14 drugs and vaccines in clinical trials and probably another 15 in development,” he said.

Basic research to develop new ways to manufacture and modify RNA, and make better nanoparticles to deliver it, is already under way in many centres around the world.

The interest, activity and investment in this new technology will likely help with the management of the next pandemic.

“Meantime, my feeling is that we will live with COVID-19 just as we live with the flu, but the therapeutics will be much better,” he said.

‍“It’s remarkable that flu vaccines are less than 50 per cent effective, and now we have mRNA vaccines that are 95 per cent effective.”

Charles Munger, vice-chairman of Berkshire Hathaway, will headline the conference. What Mr Munger is to the investment world, Professor Langer is to the biotech world.

He runs the largest academic biomedical engineering laboratory in the world, at MIT in Massachusetts, and holds more than 1400 granted or pending patents, which are licensed or sub-licensed to more than 400 companies.‍

Passionate about basic research – “you never know where it will go” – he was willing to donate his time to the virtual conference because, since 2016, Sohn Hearts & Minds has given $30 million in donated management fees to several research partners. These include the Florey Institute, The Victor Chang Cardiac Research Institute and the Children’s Hospital at Westmead.‍

When Professor Langer started working on nanoparticles in 1974, he could not have imagined the role they would play in vaccinating people in a pandemic 46 years later.

“But in 2010 [when Moderna was founded] I remember coming home and telling my wife Moderna was going to be the most successful biotech company of all time.”

When the pandemic hit, Moderna’s share price was around $US19. Today it is around $US349, and he is “very optimistic it will continue to do very well”.

“Here’s the beauty of mRNA vaccine. On 11 January 2020, the sequence of the spike protein was published. Two days later, Moderna had designed a vaccine. By March 16, the phase one trial started.‍

“The reason it was so fast is that you don’t need to grow eggs and purify things as for flu. You design it almost on a computer, make it in the laboratory, you give the body the instructions to make the spike protein, and it does all the work.”

A prolific entrepreneur, Professor Langer has participated in the founding of over 40 biotech companies and has many tips for investors in the sector. One is to make a distinction between sales and value.

‍“At Moderna, we created a lot of value before we had any sales – and while potential value is key, it’s not necessarily so easy to judge. It’s also a gamble.”

‍Being able to take a long-term view is also important. “In August 2020, I had a call from The New York Times, and the reporter asked how I could expect Moderna to produce this vaccine [it was in trials] if the company has been around 10 years and hasn’t produced the drug. I told him ’10 years seems pretty short to me’.”

How does Professor Langer manage all his business interests while focusing on research? He has never run a company and leaves that to carefully chosen people who have the expertise.‍

“I just try to give advice on boards, scientific advisory boards and founding companies. I help with the science, the innovation, sometimes recruiting scientists and troubleshooting with them. I also advise on intellectual property and contribute to strategy – it’s a team effort.”‍

But for all the enchantment with mRNA, Professor Langer can’t disagree that, ultimately, it too will be replaced some day by something superior.

“Whenever I’m asked ‘what’s next’ in terms of research, I reply it’s something that doesn’t have a name because it hasn’t been discovered yet. And that’s why basic research is so important because it’s usually where those discoveries come from.”‍

The Australian Financial Review is a media partner of the Sohn Hearts & Minds conference, which attempts to draw the finest investment ideas and insights into a single event designed to raise awareness and funding for medical research.

‍The online event is on December 3, with tickets priced at $500. https://www.sohnheartsandminds.com.au/checkout-2021

This article was originally posted by The AFR here.

Licensed by Copyright Agency. You must not copy this work without permission.

Recent Posts

Read the latest insights
A curated list of HM1 investor updates, portfolio news and other interesting articles.
Read More
Reporting Season Insights: HM1 Core Portfolio Holdings
We spoke to our dedicated fund managers for an update on some of our major portfolio holdings following reporting season.
The investing megatrends you can’t ignore (and some you should rethink)
James Marlay of Livewire sat down with Vihari Ross of Antipodes (HM1 Conference Fund Manager) and James Tsinidis of Munro Partners (HM1 Core Fund Manager) to discuss the biggest megatrends shaping the future.
2025: Where to Find Market Opportunities
There are opportunities abound for investors with an active management mindset in 2025. Get more insights from one of HM1's Core Fund managers, Magellan.
Significant increase in profit and increased fully franked dividend
We're pleased to declare an increased half-year fully franked dividend of 8.0 cents per share payable in April 2025.
 

Reporting Season Insights: HM1 Core Portfolio Holdings

We spoke to our dedicated fund managers for an update on some of our major portfolio holdings following reporting season.

Read More
March 10th, 2025
 

The investing megatrends you can’t ignore (and some you should rethink)

James Marlay of Livewire sat down with Vihari Ross of Antipodes (HM1 Conference Fund Manager) and James Tsinidis of Munro Partners (HM1 Core Fund Manager) to discuss the biggest megatrends shaping the future.

Read More
March 3rd, 2025
 

2025: Where to Find Market Opportunities

There are opportunities abound for investors with an active management mindset in 2025. Get more insights from one of HM1's Core Fund managers, Magellan.

Read More
February 25th, 2025
 

Significant increase in profit and increased fully franked dividend

We're pleased to declare an increased half-year fully franked dividend of 8.0 cents per share payable in April 2025.

Read More
February 20th, 2025
 

Magellan's Elisa Di Marco - 3 Trends That Will Define The Next Decade

Elisa Di Marco of Magellan (HM1 Core Fund Manager) joined Equity Mates to unpack 3 big megatrends shaping our world today (and how we can invest in them).

Read More
February 7th, 2025
 

Nine top stock picks to prepare your portfolio for 2025

Health care, ride-sharing, and the emerging world of YouTube entertainers are among the industries leading investors have picked for growth in 2025.

Read More
January 21st, 2025
 

Resources fundies reveal top picks ahead of ‘stellar’ 2025

Some of Australia’s biggest resources funds are gearing up for a bumper start to the new year.

Read More
January 6th, 2025
 

Qiao Ma: finding killer companies, surviving the GFC & why founders win

Qiao Ma, Portfolio Manager of the Munro Partners joins Owen Rask on The Australian Investors Podcast.

Read More
January 6th, 2025
 

10 top fund managers reveal their long-term stock picks

With valuations stretched and geopolitical tensions high, the new year offers plenty of potholes for investors. 

Read More
December 28th, 2024
 

Rikki Bannan – Don’t get caught up in momentum

Conference Fund Manager Rikki Bannan, Executive Director at IFM Investors, joins Equity Mates to discuss her standout 2023 stock pick, Telix, and explore what opportunities lie ahead.

Read More
December 19th, 2024
 

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
December 10th, 2024
 

Nick Griffin – The Nvidia story is not over

Nick Griffin, Founding Partner & Chief Investment Officer of Munro Partners joined the Equity Mates podcast in their Summer Series.

Read More
December 9th, 2024
 

HM1 CEO Succession

Hearts and Minds Investments Limited advises that Paul Rayson intends to retire from the position of Chief Executive Officer, effective 19 February 2025.

Read More
December 5th, 2024
 

How Trump will impact equity markets

The United States has spoken. President Trump has returned to the White House. But how can we cut through the noise to reveal the investment, economic and geopolitical ramifications?

Read More
November 26th, 2024
 

Trump unifies top investors in decade-long bullish outlook for US

Nick Moakes, CIO of the $72 billion Wellcome Trust, told the conference that too many investors were banking on a return to the ultra-low interest rates that prevailed over the past decade.

Read More
November 20th, 2024
 

These rock-star stock picks could get markets talking next year

Eleven rock stars of international and local funds management took to stage – each tasked with picking and pitching one company whose shares will take off over the next year.

Read More
November 18th, 2024
 

Is anyone brave or stupid enough to bet against America?

Stock pickers have been punished for betting against the US. The choice between consensus and contrarianism on American exceptionalism is now harder than ever.

Read More
November 17th, 2024
 

Sohn: NYSE-listed Estee Lauder’s Northcape Capital pick

Northcape Capital’s Fleur Wright this gives a rare opportunity to buy a high quality company at an attractive price.

Read More
November 15th, 2024
 

Sohn ASX stock pick: Ellerston Capital’s Chris Kourtis backs Perpetual

Chris Kourtis has put his biggest bet on embattled Perpetual – picking one of the most hated stocks on the ASX – that he believes will soon be the ‘cheapest listed asset manager of scale in the universe’.

Read More
November 15th, 2024
 

AI start-ups a threat to incumbent big companies

Paul Bassat predicts emerging artificial intelligence companies will disrupt sectors and overtake established incumbent companies just as rapidly as the seismic shifts that took place when the internet emerged in the mid-1990s.

Read More
November 15th, 2024
 

Howard Marks and Sohn’s big stars reveal seven rules for investing

Among the stock picks and stunts at the Sohh Hearts & Minds event, Howard Marks and Nick Moakes provided investors with long-term rules for playing markets.

Read More
November 15th, 2024
 

Sohn investors position for bullish but bumpy Trump ride

Australia and the rest of the world must adjust to a new Trump presidency that will deliver an expected bull market but also disruption, with the leader in waiting prepared to “create pain” to get his way.

Read More
November 15th, 2024
 

Sohn stock picker experts name best shares to invest in for year ahead

‍Don’t overlook down and out silver miners, legacy skincare brands ready for a revival and a big financial company suffering from a severe case of shareholder wealth destruction.

Read More
November 15th, 2024
 

Eleven stock tips from Sohn to get you through 2025

“There’s no finer place for the finance festival than in the festival city,” said Matthew Grounds. He, along with fellow Barrenjoey co-executive chairman Guy Fowler and investor Gary Weiss, is one of Sohn’s driving forces.

Read More
November 15th, 2024
 

Sohn Hearts & Minds Investments fund targets $1.5bn valuation

‍Hearts & Minds Investments chair Chris Cuffe is hoping for HM1 to grow to more than $1.5bn in the next five years.

Read More
November 14th, 2024
 

Galaxy Digital CEO Mike Novogratz believes bitcoin will hit $US100k

Bitcoin’s bounce to record highs in recent days is only the beginning of a fresh surge higher for cryptocurrency, says US billionaire Mike Novogratz.

Read More
November 9th, 2024
 

Why this New York hedge fund manager sees opportunity in European stocks

Influential New York-hedge fund manager Ricky Sandler will turn to Europe for his next stock pick.

Read More
November 6th, 2024
 

Antipodes’ Ross says short-term wealth hinges on US election

The portfolio manager says defensive stocks pose a bigger risk than the magnificent seven for investors that are overexposed to the American sharemarket.

Read More
November 5th, 2024
 

Concentration risk key for investors: Antipodes Partners’ Vihari Ross

The concentration risk in global stock indexes that has built up during the strong rise over the past year must now be a key consideration for global investors, according to Vihari Ross.

Read More
November 5th, 2024
 

The fundie betting big on China – with help from AI

Mr Mehta is sticking to his well-worn strategy: he’s hunting for companies across Asia that aren’t battling intense competition and have management teams focused on costs, cash generation and high payouts to shareholders.

Read More
November 5th, 2024